Equity Profile

ADPT

Adaptive Biotechnologies Corporation

Health CareLife Sciences Tools & Services$3.4B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Adaptive Biotechnologies Corporation specializes in life sciences tools and services, focusing on using the immune system to develop diagnostics and therapeutics. As part of the health care sector, its innovations could play a significant role in personalized medicine and disease management.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+37.94%

Avg Stock Reaction

-0.91%

Last Quarter Recap

In Q1 2026, Adaptive Biotechnologies reported an EPS of -$0.13, beating estimates by 16.13%. However, the stock fell by nearly 5% the following day, indicating market skepticism despite the positive surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Adaptive Biotechnologies are cautious, given the lack of analyst estimates and management guidance. Investors are likely looking for signs of improvement in profitability and revenue growth.

Bull Case

If the company can demonstrate strong revenue growth and continued advancements in its product pipeline, it may attract positive attention and drive the stock higher.

Bear Case

Conversely, if the company fails to show significant progress or if the market perceives its growth potential as limited, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can the company provide for its new diagnostic products?

Revenue growth in new products is critical for demonstrating market demand and the effectiveness of their innovations.

How does management view the competitive landscape and its impact on future growth?

Understanding management's perspective on competition can provide insights into the company's strategic positioning and potential challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Adaptive Biotechnologies to capture market share in the growing field of personalized medicine, especially if they can highlight strong product adoption rates.

Supporting Evidence

Options are pricing a 37.62% move, indicating expectations for significant volatility that may not align with historical performance.

The company's consistent EPS beat rate suggests that management may be more capable than the market anticipates.

Key Risk

If the company can showcase a strong pipeline and revenue growth, it could significantly alter the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show meaningful growth in its product offerings and navigate competitive pressures.

Bull Confirmed If

Demonstrating revenue growth of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is flat or negative, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.62%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±37.6% while ADPT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

53.6%

Calls (1K)P/C Ratio: 0.31Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Adaptive Biotechnologies beats expectations, history suggests the stock could rise by an average of 2.61%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may experience a muted response as investors await clearer guidance.

Miss

Should the company miss expectations, the stock could drop, with historical data suggesting an average decline of around 4.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on partnerships or collaborations that could enhance growth.
3Insights into the competitive landscape and how the company plans to differentiate itself.
4Management's outlook on revenue growth for the upcoming quarters.
5Details on cost management and operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+37.94%

Avg Stock Reaction

-0.91%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company can demonstrate strong revenue growth and continued advancements in its product pipeline, it may attract positive attention and drive the stock higher.

Bear Case

Conversely, if the company fails to show significant progress or if the market perceives its growth potential as limited, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can the company provide for its new diagnostic products?

Revenue growth in new products is critical for demonstrating market demand and the effectiveness of their innovations.

How does management view the competitive landscape and its impact on future growth?

Understanding management's perspective on competition can provide insights into the company's strategic positioning and potential challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Options are pricing a 37.62% move, indicating expectations for significant volatility that may not align with historical performance.

The company's consistent EPS beat rate suggests that management may be more capable than the market anticipates.

Key Risk

If the company can showcase a strong pipeline and revenue growth, it could significantly alter the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show meaningful growth in its product offerings and navigate competitive pressures.

Bull Confirmed If

Demonstrating revenue growth of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is flat or negative, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.62%

Historical Avg

±2.6%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±37.6% while ADPT has averaged ±2.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

53.6%

Calls (1K)P/C Ratio: 0.31Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Adaptive Biotechnologies beats expectations, history suggests the stock could rise by an average of 2.61%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may experience a muted response as investors await clearer guidance.

Miss

Should the company miss expectations, the stock could drop, with historical data suggesting an average decline of around 4.97%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on partnerships or collaborations that could enhance growth.
3Insights into the competitive landscape and how the company plans to differentiate itself.
4Management's outlook on revenue growth for the upcoming quarters.
5Details on cost management and operational efficiency improvements.